The first major achievement in the treatment of systemic fungal infections occurred a quarter of a century ago with the discovery of amphotericin B. For many years this polyene has been the staple for systemic antifungal therapy, although preparations such as potassium iodide, hydroxystilbamidine and sulfonamides have been effective in the treatment of certain of the deep mycoses. Within the past decade three new drugs have been licensed for systemic treatment of fungal diseases: Flucytosine in 1972, miconazole in 1978 and ketoconazole in 1981. While these agents are welcomed additions to the antimicrobial armamentarium, the physician is now faced with the task of selecting the most appropriate treatment regimen for the patient with a severe fungal infection. The intent of this commentary is to attempt to place in some perspective the four drugs currently available for the treatment of systemic mycoses.
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Microbiology (medical)